Literature DB >> 19361956

X-linked primary immunodeficiencies as a bridge to better understanding X-chromosome related autoimmunity.

Itai M Pessach1, Luigi D Notarangelo.   

Abstract

Recent studies indicate that genes located on the X-chromosome play a major and unique role in autoimmunity. The fact that most X-linked primary immune deficiencies carry significant autoimmune manifestations greatly supports this notion. Autoimmunity and immune deficiency have been considered two opposite extremes resulting from immune dysregulation and failure of immune development and/or function, respectively. Growing evidence has been accumulating to indicate that autoimmune phenomena occur in patients suffering from primary immune deficiency (PID), and the molecular and cellular mechanisms that interconnect these conditions are being unraveled. The study of rare single-gene disorders associated with significant autoimmunity may shed light on the pathophysiology of more complex multifactorial and polygenic autoimmune disorders. In this regard, primary immunodeficiencies represent unique "experiments of Nature" that illustrate the critical role played by single-gene products in the development, function and homeostasis of the immune system. In this review we will focus on the clinical features and on the cellular and molecular pathophysiology of the known X-linked PID in which autoimmune manifestations are more common, in the attempt to understand what single-gene defects can teach us on the role that key immune pathways and cellular processes may play to prevent autoimmunity.

Entities:  

Mesh:

Year:  2009        PMID: 19361956     DOI: 10.1016/j.jaut.2009.03.003

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  20 in total

1.  A contemporary update on scleroderma.

Authors:  Loïc Guillevin
Journal:  Clin Rev Allergy Immunol       Date:  2011-04       Impact factor: 8.667

Review 2.  The sex bias in systemic sclerosis: on the possible mechanisms underlying the female disease preponderance.

Authors:  Fabio D'Amico; Evangelia Skarmoutsou; Maria Clorinda Mazzarino
Journal:  Clin Rev Allergy Immunol       Date:  2014-12       Impact factor: 8.667

Review 3.  Update on primary biliary cirrhosis.

Authors:  Pietro Invernizzi; Carlo Selmi; M Eric Gershwin
Journal:  Dig Liver Dis       Date:  2010-03-31       Impact factor: 4.088

4.  Autoimmune disorders in women with turner syndrome and women with karyotypically normal primary ovarian insufficiency.

Authors:  Vladimir K Bakalov; Liat Gutin; Clara M Cheng; Jian Zhou; Puja Sheth; Kavita Shah; Sruthi Arepalli; Vien Vanderhoof; Lawrence M Nelson; Carolyn A Bondy
Journal:  J Autoimmun       Date:  2012-02-18       Impact factor: 7.094

Review 5.  Primary biliary cholangitis: new treatments for an old disease.

Authors:  Hirsh D Trivedi; Blanca Lizaola; Elliot B Tapper; Alan Bonder
Journal:  Frontline Gastroenterol       Date:  2016-11-03

Review 6.  The X chromosome in immune functions: when a chromosome makes the difference.

Authors:  Claude Libert; Lien Dejager; Iris Pinheiro
Journal:  Nat Rev Immunol       Date:  2010-08       Impact factor: 53.106

7.  A novel deletion mutation in IL2RG gene results in X-linked severe combined immunodeficiency with an atypical phenotype.

Authors:  Wenjun Mou; Jianxin He; Xi Chen; Hui Zhang; Xiaoya Ren; Xunyao Wu; Xin Ni; Baoping Xu; Jingang Gui
Journal:  Immunogenetics       Date:  2016-08-26       Impact factor: 2.846

8.  Genomic variants associated with primary biliary cirrhosis.

Authors:  Carlo Selmi; Natalie J Torok; Andrea Affronti; M Eric Gershwin
Journal:  Genome Med       Date:  2010-01-26       Impact factor: 11.117

Review 9.  Rheumatologic manifestations of primary immunodeficiency diseases.

Authors:  V R Dimitriades; R Sorensen
Journal:  Clin Rheumatol       Date:  2016-03-14       Impact factor: 2.980

Review 10.  Autoimmunity in immunodeficiency.

Authors:  Krista Todoric; Jessica B Koontz; Daniel Mattox; Teresa K Tarrant
Journal:  Curr Allergy Asthma Rep       Date:  2013-08       Impact factor: 4.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.